Table 2: summary of findings table for Nitazoxanide versus placebo in HIV-infected and -exposed children with cryptosporidial diarrhoea

Patient or population: HIV-infected and HIV-exposed children with cryptosporidial diarrhoea
Settings: Tertiary hospital in Zambia
Intervention: Nitazoxanide versus placebo

Outcomes

Illustrative comparative risks+ (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

Nitazoxanide

Clinical cure
Last unformed stool assessed by clinician
Follow-up: 7 days

See comment

See comment

Not estimable

50
(1 study)

⊕⊕⊝⊝
low1

N/A

All-cause mortality
Assessed by hospital personnel
Follow-up: 8 days

See comment

See comment

Not estimable

50
(1 study)

⊕⊕⊝⊝
low1

N/A

+The basis for the assumed risk is the control group risk across the included studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

1 Downgraded by two points for imprecision: only one small study reported on this outcome

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate